16,418 Shares of Illumina, Inc. $ILMN Bought by Ninety One North America Inc.

Ninety One North America Inc. purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 16,418 shares of the life sciences company’s stock, valued at approximately $4,493,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Illumina in the 2nd quarter worth about $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina during the 2nd quarter worth about $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter worth about $358,652,000. WCM Investment Management LLC lifted its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Illumina during the second quarter valued at about $293,846,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 1.1%

NASDAQ ILMN traded down $2.92 during trading on Thursday, reaching $268.85. 1,367,740 shares of the company’s stock were exchanged, compared to its average volume of 2,166,710. Illumina, Inc. has a fifty-two week low of $93.50 and a fifty-two week high of $309.35. The firm has a market capitalization of $40.60 billion, a PE ratio of 50.14, a P/E/G ratio of 3.84 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company’s fifty day simple moving average is $231.55 and its 200-day simple moving average is $184.42.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,061,850 shares of company stock worth $436,479,102 over the last quarter. Insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ILMN. Piper Sandler lifted their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Citigroup raised their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Finally, TD Cowen raised their price objective on shares of Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a research note on Tuesday. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $225.94.

Illumina Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.